Oncogenic role of SOX9 expression in human malignant glioma
- 20 June 2012
- journal article
- Published by Springer Nature in Medical Oncology
- Vol. 29 (5) , 3484-3490
Abstract
SOX9 belongs to the SOX (Sry-related high-mobility group box) family and acts as a transcription factor that plays a central role in the development and differentiation of multiple cell lineages. Recent studies have demonstrated that SOX9 is required for the carcinogenesis in several cancer types. The aim of this study was to investigate the clinicopathological significance of SOX9 expression in human malignant glioma. SOX9 mRNA expression was detected by real-time quantitative RT-PCR assay in glioma and nonneoplastic brain tissues. Then, the association of SOX9 mRNA expression with clinicopathological factors or prognosis of glioma patients was statistically analyzed. In addition, the small interfering RNA was used to knockdown SOX9 expression in a glioma cell line and to analyze the effects of SOX9 inhibition on cell growth, cell cycle and apoptosis of glioma cell line. The expression level of SOX9 mRNA in glioma tissues was significantly higher than that in corresponding nonneoplastic brain tissues (P < 0.001). In addition, a high level of SOX9 mRNA expression was significantly more common in glioma tissues with advanced WHO grade than those with low grade (P = 0.02). The increased expression of SOX9 mRNA was also significantly correlated with low Karnofsky performance score (P = 0.008). Meanwhile, the disease-free and overall survival rates of patients with high SOX9 mRNA expression were obviously lower than those of patients with low SOX9 mRNA expression (both P = 0.01). Multivariate analysis showed that high SOX9 mRNA expression was an independent prognostic factor for glioma patients (P = 0.02). Moreover, the down-regulation of SOX9 could inhibit the cell growth, induce the cell arrest in G2/M phase of cell cycle and enhance the apoptosis in glioma cells. Our data suggest for the first time that the over-expression of SOX9 mRNA is closely associated with poor clinical outcome of patients with malignant gliomas, and targeting SOX9 may be a novel therapeutic strategy for this tumor.Keywords
This publication has 22 references indexed in Scilit:
- SOX9 is expressed in normal stomach, intestinal metaplasia, and gastric carcinoma in humansJournal of Gastroenterology, 2011
- Cerebellar stem cells act as medulloblastoma-initiating cells in a mouse model and a neural stem cell signature characterizes a subset of human medulloblastomasOncogene, 2010
- Upregulation of SOX9 inhibits the growth of human and mouse melanomas and restores their sensitivity to retinoic acidJournal of Clinical Investigation, 2009
- Analysis of SOX9 Expression in Colorectal CancerAmerican Journal of Clinical Pathology, 2008
- SOX9 expression is a general marker of basal cell carcinoma and adnexal‐related neoplasmsJournal of Cutaneous Pathology, 2008
- FOXL2 and SOX9 as parameters of female and male gonadal differentiation in patients with various forms of disorders of sex development (DSD)The Journal of Pathology, 2008
- Identification of DNA hypermethylation of SOX9 in association with bladder cancer progression using CpG microarraysBritish Journal of Cancer, 2007
- Expression and biological role of the prostaglandin D synthase/SOX9 pathway in human ovarian cancer cellsCancer Letters, 2007
- The 2007 WHO Classification of Tumours of the Central Nervous SystemActa Neuropathologica, 2007
- A nuclear export signal within the high mobility group domain regulates the nucleocytoplasmic translocation of SOX9 during sexual determinationProceedings of the National Academy of Sciences, 2002